LEIDEN, the Netherlands--(

荷兰莱顿--(

BUSINESS WIRE

商业热线

)--Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses..

)--Leyden Laboratories B.V.（“公司”或“Leyden Labs”）今天宣布，已筹集7000万美元资金，用于推进其粘膜保护平台。这种非疫苗方法利用广泛的鼻内保护性抗体，使人们免受呼吸道病毒（如流感和冠状病毒）的威胁。。

The funding round was supported by co-leads ClavystBio (a life sciences venture investor established by Temasek) and Polaris Partners, with participation by Qiming Venture Partners and existing investors. The Company’s syndicate of VC investors now includes GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio, Polaris Partners, Qiming Venture Partners, Invus, Byers Capital / Brook Byers, Bluebird Ventures, and Softbank Vision Fund 2..

这轮融资得到了联合牵头人ClavystBio（淡马锡成立的生命科学风险投资公司）和Polaris Partners的支持，启明风险投资公司和现有投资者也参与了这轮融资。该公司的风险投资财团现在包括GV（以前的谷歌风险投资）、Casdin Capital、F-Prime Capital、ClavystBio、Polaris Partners、Qiming Venture Partners、Invus、Byers Capital/Brook Byers、Bluebird Ventures和Softbank Vision Fund 2。。

Proceeds from the funding round will support further development of the Company’s pipeline aimed at providing protection against respiratory viruses, such as influenza and coronaviruses. Leyden Labs is advancing a novel class of broadly protective nasal sprays, including its PanFlu candidate containing the monoclonal antibody CR9114 which is currently in development for influenza prophylaxis.

融资回合的收益将支持该公司管道的进一步发展，旨在提供针对流感和冠状病毒等呼吸道病毒的保护。莱顿实验室正在开发一类新型的广泛保护性鼻喷雾剂，包括其含有单克隆抗体CR9114的泛流感候选药物，目前正在开发用于预防流感。

The funding will support the initiation of human efficacy studies of PanFlu, advancements in the Company’s Mucosal Protection Platform research, and other pipeline activities..

该资金将支持启动PanFlu的人体功效研究，公司粘膜保护平台研究的进展以及其他管道活动。。

“This strong support from investors validates our approach to providing broad, universal protection against current and future viral outbreaks,” said Koenraad Wiedhaup, co-founder and chief executive officer of Leyden Labs. “At Leyden Labs, we’re working to stop infections early by delivering antibody-based formulations directly to the nasal mucosa – eliminating the threat of respiratory viruses directly at the very gate through which they enter.

莱顿实验室联合创始人兼首席执行官科恩拉德·维德豪普（Koenraad Wiedhaup）表示：“投资者的大力支持验证了我们针对当前和未来病毒爆发提供广泛、普遍保护的方法。”。“在莱顿实验室，我们正在努力通过将基于抗体的制剂直接输送到鼻粘膜来尽早阻止感染，从而消除呼吸道病毒直接进入其入口的威胁。

The timing of this fundraising is critical – in light of recent avian flu (H5N1) developments, we feel even more urgency to execute on our mission to protect people against existing and new viruses.”.

这次筹资的时机至关重要——鉴于最近禽流感（H5N1）的发展，我们感到更加迫切需要执行我们的使命，保护人们免受现有和新病毒的侵害。”。

“We are pleased to partner with Leyden Labs to advance the mission of protecting the world from the burden of known and new respiratory viruses,” said Khoo Shih, chief executive officer of ClavystBio, who joins the Supervisory Board of Leyden Labs. “This demonstrates our strong commitment to working with world-class scientists and passionate leaders at Leyden Labs to accelerate the development of its novel technology and pipeline to make a global health impact.”.

加入莱顿实验室监事会的ClavystBio首席执行官Khoo Shih表示：“我们很高兴与莱顿实验室合作，推进保护世界免受已知和新呼吸道病毒负担的使命。”。“这表明我们坚定地致力于与莱顿实验室的世界级科学家和充满激情的领导者合作，加速其新技术和管道的开发，以对全球健康产生影响。”。

In addition to this financing, the Company announces the acquisition of CoV Biotechnology Pte. Ltd., a Singapore-based biotech company with assets developed by Linfa Wang, a professor of emerging infectious diseases at Duke-NUS Medical School. This acquisition adds to Leyden Labs’ research and development efforts including pandemic preparedness and other partnership initiatives in Asia..

除此之外，该公司宣布收购CoV Biotechnology Pte.Ltd.，这是一家总部位于新加坡的生物技术公司，其资产由杜克国立大学医学院新兴传染病教授Linfa Wang开发。此次收购增加了莱顿实验室的研发工作，包括大流行防范和亚洲的其他合作计划。。

Leyden Labs looks forward to presenting this financing and the team’s latest progress at the upcoming JP Morgan Annual Healthcare Conference.

莱顿实验室期待着在即将举行的摩根大通年度医疗会议上介绍这项融资和团队的最新进展。

About Leyden Laboratories B.V.

关于Leyden Laboratories B.V。

Leyden Labs is working to free people from the threat of respiratory viruses. Leyden Labs is leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays.

莱顿实验室正在努力使人们免受呼吸道病毒的威胁。莱顿实验室正在利用其粘膜保护平台开发一系列候选药物，旨在通过一类新的广泛保护性鼻喷雾剂提供针对流感，冠状病毒和其他呼吸道病毒的保护。

To learn more, visit .

要了解更多信息，请访问。

www.leydenlabs.com

www.leydenlabs.com

.

.

About PanFlu candidate CR9114

关于泛流感候选人CR9114

CR9114, Leyden Labs’ lead product candidate for the PanFlu program, is a human monoclonal antibody that protects against influenza in preclinical models. Leyden Labs holds an exclusive license from Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize CR9114..

CR9114是莱顿实验室PanFlu项目的主要候选产品，是一种人类单克隆抗体，可在临床前模型中预防流感。莱顿实验室拥有强生公司杨森制药公司（Janssen Pharmaceuticals，Inc.）的独家许可证，可开发CR9114并将其商业化。。